Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration.
Alice SýkorováFrantišek FolberKamila PolgárováHeidi MócikováJuraj ĎurašKateřina SteinerováAleš ObrAdriana HeindorferMiriam LadickáĽubica LukáčováErika ČellárováIvana PlameňováDavid BeladaAndrea JaníkováMarek TrněnýTereza JančárkováVít ProcházkaAndrej VranovskýMargaréta KrálikováJan VydraLukáš SmolejĽuboš DrgoňaMartin SedminaEva ČermákováRobert PytlíkPublished in: Cancer medicine (2024)
Our findings allow better stratification of CAR-Tx candidates and stress the need for a proactive approach (earlier restaging, intervention after partial remission achievement).